Sign inJoin waitlistJoin the waitlist

Jason Mouabbi

Assistant Professor, Breast Medical Oncology · The University of Texas MD Anderson Cancer Center

Credentials: · · · · · · ·

History

Baylor
2021–2022
Baylor College of Medicine
2020–2021
Hematology and Medical Oncology
Henry Ford St. John Hospital
2017–2020
Ascension St. John Hospital
2014–2017
Doctor of Medicine
2010–2014

Research

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer
Review · Breast Cancer Research and Treatment · 2022 · First of 6 authors · Corresponding · 97 citations
Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol
Journal of Nuclear Medicine · 2023 · 73 citations
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
Review · Cancers · 2023 · 25 citations

DT
Debasish Tripathy
6 papers
Kelly Hunt
6 papers
Rachel Layman
6 papers
Amy Hassan
5 papers
Senthil Damodaran
4 papers
Vicente Valero
4 papers
Anthony Lucci
3 papers
Carlos Barcenas
3 papers
Funda Meric-Bernstam
3 papers
Helen Johnson
3 papers
Henry Kuerer
3 papers
JO
Joyce O'Shaughnessy
3 papers

Clinical trials

A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2029
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2024–2025
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Site PI · Recruiting · Phase 1
Stemline Therapeutics, Inc.
2024–2029
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2030